equinet Reiterates €24.10 Price Target for Biotest (BIO)

Biotest (ETR:BIO) received a €24.10 ($27.39) price target from analysts at equinet in a report released on Wednesday. The firm presently has a “neutral” rating on the stock. equinet’s target price would indicate a potential upside of 0.42% from the stock’s previous close.

Shares of ETR BIO opened at €24.00 ($27.27) on Wednesday. Biotest has a 52-week low of €18.70 ($21.25) and a 52-week high of €32.20 ($36.59).

About Biotest



Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas.

Recommended Story: What is the Book Value of a Share?

Receive News & Ratings for Biotest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotest and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply